Abrocitinib and Enzalutamide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong or moderate CYP2C19 induction can reduce combined abrocitinib active-moiety exposure.
Clinical significance and safety
Enzalutamide contains an inducer that meets the abrocitinib label’s CYP2C19 interaction criteria. Reduced exposure can weaken treatment response, and coadministration should be avoided according to the label. A specialist should choose an appropriate plan; changing the dose from a website is unsafe.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.